64
Arrhythmia ABDULLAH

Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Embed Size (px)

Citation preview

Page 1: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Arrhythmia

ABDULLAH M.Pharm

(Pharmacy Practice) 1st SemFaculty of Pharmacy Jamia Hamdard

Page 2: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

DEFINATION

Cardiac Arrhythmia is a condition in which the heart beats with an irregular or abnormal rhythm.

Page 3: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

ABNORMAL RHYTHM

CAN BE OF TWO EXTREME FORMS

1. Bradycardia - Cardiac beats below 60 beats per minute .

2. Tachycardia – Cardiac beat above 100 beats per minute.

Page 4: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

ETIOLOGY Coronary artery disease. Electrolyte imbalances in your blood

(such as sodium or potassium). Changes in your heart muscle. Injury from a heart attack.

Page 5: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Healing process after heart surgery. Irregular heart rhythms can also

occur in "normal, healthy" hearts. Ischemic Heart Disease Drugs related Others

Page 6: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Arrhythmia Presentation (SYMPTOMS)

Palpitation. Dizziness. Chest Pain. Dyspnea.

Page 7: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Fainting. Sudden cardiac death Swelling Shortness of Breath Exercise Intolerance

Page 8: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Mechanism of Arrhythmias Bradycardia1. SA node : Slowed / AbsentCauses• Decreased Sympathetic Signals• Increased Parasympathetic Signals• SA node Damage

Page 9: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)
Page 10: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

2. Blockage of Conduction from SA node

AV node BlockageCauses• Ischemia • Fibrosis• Viral Infection

RESULTS in HEART ATTACK

Page 11: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)
Page 12: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

LEFT BUNDLE BRUNCH BLOCK (LBBB)• No Impulse conduction through

Bundle Brunch• Action Potential transferred through

Right Ventricle to Left Ventricle

RESULTS in Wide QRS complex

Page 13: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)
Page 14: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Tachycardia1. Increased Pacemaker Activity (SA

Node)- Sinus Tachycardia Causes• Increased Sympathetic Signals• Decreased Parasympathetic Signals• SA node Dysfunction Example : Sick Sinus Syndrome

Page 15: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

2.Re-entry Tachycardias Atrial Fibrillation

Page 16: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

• loss of the normal organised propagation of electrical activity

• atria fibrillate, they no longer contract in a mechanically useful way

• a degree of stasis to blood flow and predisposing to clot (thrombus) formation within the chambers

Page 17: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Ventricular Fibrillation

Page 18: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

•  Uncoordinated contraction of the Cardiac Muscle

• Quiver rather than contract properly

• Commonly identified arrhythmia in Cardiac Arrest patients

• As a consequence, Sudden Cardiac Death

Page 19: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Wolf Parkinson White Syndrome (WPW)

Page 20: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

• WPW is caused by the presence of an abnormal accessory electrical conduction pathway between the atria and the ventricles. 

• Electrical Signals through abnormal pathway  stimulate the ventricles to contract prematurely

• A unique type of supraventricular tachycardia referred to as an ”atrioventricular reciprocating tachycardia”.

Page 21: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Atrioventricular nodal re-entrant tachycardia

• Most common regular supraventricular tachycardia

•  Re-entry circuit forms within or just next to the atrioventricular node.

• Same as WPW except reentry is in or around AV node

Page 22: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

3. Delayed Repolarization

Page 23: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Causes

• Ischemia • Drugs related (Potassium Blockers)• Electrolyte Imbalance

Page 24: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Effects

Long QT intervalR on T PhenomenonPremature Ventricular BeatVentricular Fibrillation

Page 25: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)
Page 26: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

PHARMACOTHERAPY

Page 27: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Class Action Drugs

I A. Na Channel blockers Quinidine, procainamide

I B. Na Channel blockers Lidocaine

I C. Na Channel blockers Flecainide

II Beta-adrenergic blockers Propranolol, esmolol

III Prolong repolarization Amiodarone, Sotolol

Dofetalide, ibutilide

IV Calcium channel blockers Verapamil, diltiazem

Page 28: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Class I: Sodium Channel Blockers (Local Anesthetics)

Page 29: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Class 1A agents:• Procainamide• quinidine • disopyramide   Effects on cardiac activity• conduction

Page 30: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

• refractory period ( (K+) and Na inactivation)

• automaticity • increase threshold (Na+)

Quinidine has anticholinergic (atropine like action) to speed AV conduction used with digitalis, β blocker or Ca channel blocker

• Quinidine is also an alpha receptor antagonist

Page 31: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses

Quinidine : maintain sinus rhythms in atrial fibrillation and flutter and to prevent recurrent tachycardia and fibrillation  

Procainamide: acute treatment of supraventricular and ventricular arrhythmias  

   

Page 32: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Side effects• Hypotension, reduced cardiac

output• Proarrhythmia (generation of a new

arrhythmia)• Dizziness, confusion, insomnia,

seizure (highdose)•  Gastrointestinal effects (common)

Page 33: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Class 1B agents: • Lidocaine • mexiletine • Henytoin

AdministrationLidocaine: iv only

      Tocainide and mexiletine: oral      

Page 34: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Effects on cardiac activity

• APD slightly decreased (normal tissue)

• increase threshold (Na+)

Page 35: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses• Acute : Ventricular tachycardia

and fibrillation (esp. during ischemia)

• Not used in atrial arrhythmias or AV junctional arrhythmias

      Side effects  CNS effects: dizziness, drowsiness

Page 36: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Class 1C agents:• Flecainide • propafenone              Effects on cardiac activity• automoticity ( threshold)

• APD (K+) and refractory period, especially in rapidly depolarizing atrial tissue.

                   

Page 37: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses• Wide spectrum• Used for supraventricular

arrhythmias (fibrillation and flutter)

• Premature ventricular contractions (caused problems)

• Wolff-Parkinson-White syndrome

Page 38: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Side effects• Proarrhythmia and sudden

death especially with chronic use • increase ventricular response to

supraventricular arrhythmias• CNS and gastrointestinal effects

like other local anesthetics

Page 39: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

CLASS II :BETA-ADRENOCEPTOR-BLOCKING DRUGS

Page 40: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Class II agents:• propranolol • acebutolol • esmolol

Administration Propranolol: oral, iv Esmolol: iv only (very short acting T½, 9 min)

Page 41: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Cardiac effects

• APD and refractory period in AV node to slow AV conduction velocity

Page 42: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses• Treating sinus and

catecholamine dependent tachyarrhythmias

• converting reentrant arrhythmias in AV

• protecting the ventricles from high atrial rates (slow AV

conduction)

Page 43: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Side effects

• bronchospasm•  hypotension• don’t use in partial AV block or

ventricular failure

Page 44: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

CLASS III - Drugs That Prolong Effective Refractory Period By Prolonging the Action Potential

Page 45: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Class III agents:• amiodarone• sotalol • Ibutilide• dofetilide

Amiodarone

AdministrationOral or iv (T 1/2 about 3 months)

Page 46: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Cardiac effects

• increase refractory period and APD (K+)

•   conduction (Na+)•    (β block and Ca++ block)•   speed of AV conduction

Page 47: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses• Very wide spectrum: effective for most

arrhythmias

Side effects: Many serious that increase with time• Pulmonary fibrosis• Hepatic injury• Increase LDL cholesterol• Thyroid disease• Photosensitivity

Page 48: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Sotolol

Administration-oral

Cardiac effects• APD and refractory period in

atrial and ventricular tissue

Page 49: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses• Wide spectrum: supraventricular and

ventricular tachycardia              Side effects• Proarrhythmia, • Fatigue• insomnia

Page 50: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Ibutilide

Administration- iv infusion

Cardiac effects

• Result in APD

Page 51: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses• conversion of atrial fibrillation and

flutter         

Side effects• Torsades de pointes

Page 52: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Dofetilide

Administration- oral

Cardiac effects• APD and refractory period

Page 53: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses• maintain sinus rhythm in atrial

fibrillation               Side effects• restricted use• Torsades de pointes

Page 54: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

CLASS IV- CALCIUM CHANNEL-BLOCKING DRUGS

Page 55: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Class IV agents: • verapamil • diltiazem

Administration verapamil: oral or i.v.diltiazem: oral

Page 56: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Cardiac effects

• slow conduction through AV (Ca++)• refractory period in AV node

Page 57: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses• control ventricles during

supraventricular tachycardia• convert supraventricular

tachycardia (re-entry around AV)

Side effects• Caution when hypotension,

decreased CO or sick sinus.Some gastrointestinal problems

Page 58: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

ADDITIONAL ANTIARRYHTHMIC AGENTS

Page 59: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Adenosine

Adminsitration                     rapid i.v. bolus, very short T1/2 (seconds)

Cardiac effects• Slows AV conduction

Page 60: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses

• convert re-entrant supraventricular arrhythmias

• hypotension during surgery, diagnosis of CAD

Page 61: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Digioxin (cardiac glycosides)

Mechanism• Enhances vagal activity(10th

Cranial Nerve)• ( K+ currents, Ca++ currents,

refractory period• slows AV conduction and slows

HR

Page 62: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

Uses

• Treatment of atrial fibrillation and flutter

Page 63: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

AtropineMechanism• selective muscarinic antagonist Cardiac effects• block vagal activity to speed AV conduction and

increase HR

Uses• treat vagal bradycardia

Magnesium• treatment for tachycardia resulting from long QT

Page 64: Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)

References

Basic and Clinical Pharmacology Katzung 13 Edition Pharmacotherapy Handbook - Ninth Edition by Barbara

G. Wells (Author), Joseph T. Dipiro (Author), Terry L. Schwinghammer (Author)

www.youtube.com - Pathophysiology of Cardiac Arrhythmias by Andrew Wolf

Wikipedia